HUE032560T2 - Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása - Google Patents
Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása Download PDFInfo
- Publication number
- HUE032560T2 HUE032560T2 HUE11799979A HUE11799979A HUE032560T2 HU E032560 T2 HUE032560 T2 HU E032560T2 HU E11799979 A HUE11799979 A HU E11799979A HU E11799979 A HUE11799979 A HU E11799979A HU E032560 T2 HUE032560 T2 HU E032560T2
- Authority
- HU
- Hungary
- Prior art keywords
- rhdl
- formulation
- cholate
- apo
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (3)
- L IkMáöli «a&y s&dsegd ({rHÄ}' iâsa^rafe* ssply fspgmemdi:; 1oS:#;f«äj|>Sifoi ; és epesót vagy «p^vskMrS&giii! 0,.5 -0,5 g/L köncsabráejóbaa. '$. A® 1, igôeyp»«l saerfsO dllïL a® epssô ivsgy ppesav kö8<:gh0;ác;id|g kÓiÉibelif ^ÛlSlkOlO g/g aponpopmieb'h 3< A® !. vsgy 2, ígáoyp-ösíís®snoti TBD&kitoF#à§, hkd m«$&sê vagy sppsav öálAapOlgiát 4, te s|l# tpnypptek Sfenelyik® sæeîàsl 11« tlUM, itomls, ahol a®/äp«!spprp«i8 vljgy IVagmense.
- 5, AzelOxO í|s#3^eRlöfe:BÍTOáy^«· xzersMkrHBL kls®<a'eiés, ate! föxrfo lipid fosxíaiidiitete, 4Jm <slSs«Ô ^^»îîôikMmïiî^yls« ssteki: îte rHDL ksxzemkis, ahol s kî^reldl sísfeíI®áíÖ$K«0: h tóíialma®.
- 7. Bgtex a kOslltetekei ïam1»^S MM·· fcisgsteés elMi&hâra: agölspsprsjfcm' 4..'Κθφ;0, ^ sk?5çrge«A apply ®S|Äs magába« fegfsija m eppsd .vagy :e$J«sav iÉiiæteftèsàRsfc. láp&ií kMpäÄJ' %5 :- iyS git-koneentrációban a* rHDL kisxere&xbe».: W& Ύ<·. :%feyp£H$i .Mái eljárás, gte! ;a® egssà vagy ppeaav kespgikrâeâôja: kOKlbsi®! 0331541,010 g/g ap;dsp;>pmtesv f), A 7. vagy 0. igényper ^irÄvllPL,kis®»rÄ’g8böf az epesd vagy Sfpss« «àtriaa^fes ÎU. A ?-9. saany-pisatok: bármelyik® s®«f1atl sljânls, als«! ä® spoOpPpiPSp*0 Apm-ÁI vagy 0'ägmense.: IL A ? If; iglnypOïsUîk bármelyik® mninl! eljárás, ab«! a Il A ·»-! \ ígétiypoalok bármelyike xaennii eljárás, amely a kövelkegáláptekei fogsslp spgábim: í A) sgpswsölíMsap' Aalköís Bxsteklíiteim es !ρ||! deíergeos hömisdáxái: Agg-AO «ÄOaso |B) a köíát deîageas · teiftÉa§^3á|Mk vsbkkegídsál a® IA) Mpéteeli teisjfe* kOslibspl40¾¾ Λρ«·Α I szi«im; |€) sisb!lisátöSK«f iKígppásái a (M lépOsibeii «Idashe®, lí .A 7- Í2. ígó«vpö«iök bármelyike aaeriöií blkbássai aldálHfeiá ríBOL khzmlés. li, a® 1·ί>· igéípptete vagy 13. igé«y|xmibáímeíyik«A®eílf0rrlB5L:k1s®»í«i«s, lPíiefs#>^^mnpilaftssség va^· álleppí: «ïfiPrb«« veié ksxefêsëten idpôkô ;0k«!ms®|sm Ili Λ 14. Igényposi sv.srhrd rl l Dl, kiszerelés alkalmazásra. ah«! a betegség, «sadeiteassseg vagy áliapsi kasdsövasíkiOáP b«íags% h?pertefei?iPfí#m& vsgy:h{pök«fes2ierio®«íÍ!S. 14 Λ 15.igPppite szerints rílBL kiszerelés alkalmazásra, sises a betegség, re«Kkíls«exseg vágyállapé akui köförs# 4 sglfiikitea ;|ACi$j, afe»8®klsí®®is vagy miftkárd iáfe tóárMsp
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35992510P | 2010-06-30 | 2010-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032560T2 true HUE032560T2 (hu) | 2017-09-28 |
Family
ID=45401226
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11799979A HUE032560T2 (hu) | 2010-06-30 | 2011-06-30 | Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása |
HUE16203579A HUE042391T2 (hu) | 2010-06-30 | 2011-06-30 | Visszaoldott nagysûrûségû lipoprotein kiszerelés és elõállítási eljárása |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16203579A HUE042391T2 (hu) | 2010-06-30 | 2011-06-30 | Visszaoldott nagysûrûségû lipoprotein kiszerelés és elõállítási eljárása |
Country Status (17)
Country | Link |
---|---|
US (5) | US8999920B2 (hu) |
EP (3) | EP3178481B1 (hu) |
JP (2) | JP5989641B2 (hu) |
KR (1) | KR101782309B1 (hu) |
CN (2) | CN105396122B (hu) |
AU (1) | AU2011274238B2 (hu) |
CA (1) | CA2803031C (hu) |
DK (2) | DK3178481T3 (hu) |
ES (2) | ES2718234T3 (hu) |
HU (2) | HUE032560T2 (hu) |
IL (1) | IL223815A (hu) |
MX (1) | MX2012014928A (hu) |
PL (2) | PL2588113T3 (hu) |
SG (1) | SG186386A1 (hu) |
TR (1) | TR201903209T4 (hu) |
TW (1) | TWI531388B (hu) |
WO (1) | WO2012000048A1 (hu) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2588113T3 (pl) | 2010-06-30 | 2017-06-30 | Csl Limited | Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji |
US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药(集团)股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
JP6404333B2 (ja) * | 2013-06-05 | 2018-10-10 | シーエスエル、リミテッド | アポリポタンパク質a−i(アポa−i)の製造方法 |
KR102437202B1 (ko) | 2013-08-08 | 2022-08-29 | 시에스엘 리미티드 | 오염 제거 방법 |
EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
KR101563403B1 (ko) * | 2013-11-05 | 2015-10-26 | 영남대학교 산학협력단 | 지방물질의 안전성 평가방법 |
SG11201609084QA (en) | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
EP3238746B1 (en) * | 2014-12-25 | 2023-12-20 | Kyoto University | High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein |
EP3490579A1 (en) | 2016-07-27 | 2019-06-05 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
CN109922810A (zh) | 2016-11-10 | 2019-06-21 | 杰特有限公司 | 心肌梗塞的重构的高密度脂蛋白治疗 |
CN111601614A (zh) * | 2017-11-07 | 2020-08-28 | 阿尔法科制药有限责任公司 | 治疗和预防心脏病、心血管疾病及相关病症和症状的方法 |
WO2019133358A2 (en) * | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
BR0212880A (pt) | 2001-09-28 | 2005-12-13 | Esperion Therapeutics Inc | Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica |
MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ApoA-I의 정제방법 및 정제된ApoA-I을 이용한재구축 HDL의 생산 방법 |
WO2009025754A2 (en) | 2007-08-17 | 2009-02-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
WO2010057203A2 (en) * | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
PL2588113T3 (pl) | 2010-06-30 | 2017-06-30 | Csl Limited | Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji |
ES2717455T3 (es) | 2011-02-07 | 2019-06-21 | Cerenis Therapeutics Holding Sa | Complejos de lipoproteínas y fabricación y usos de los mismos |
US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2011
- 2011-06-30 PL PL11799979T patent/PL2588113T3/pl unknown
- 2011-06-30 HU HUE11799979A patent/HUE032560T2/hu unknown
- 2011-06-30 KR KR1020137002377A patent/KR101782309B1/ko active IP Right Grant
- 2011-06-30 ES ES16203579T patent/ES2718234T3/es active Active
- 2011-06-30 CN CN201510593566.4A patent/CN105396122B/zh active Active
- 2011-06-30 TR TR2019/03209T patent/TR201903209T4/tr unknown
- 2011-06-30 WO PCT/AU2011/000819 patent/WO2012000048A1/en active Application Filing
- 2011-06-30 CN CN201180036314.1A patent/CN103118683B/zh active Active
- 2011-06-30 PL PL16203579T patent/PL3178481T3/pl unknown
- 2011-06-30 EP EP16203579.4A patent/EP3178481B1/en active Active
- 2011-06-30 CA CA2803031A patent/CA2803031C/en active Active
- 2011-06-30 AU AU2011274238A patent/AU2011274238B2/en active Active
- 2011-06-30 DK DK16203579.4T patent/DK3178481T3/en active
- 2011-06-30 SG SG2012093076A patent/SG186386A1/en unknown
- 2011-06-30 ES ES11799979.7T patent/ES2617977T3/es active Active
- 2011-06-30 HU HUE16203579A patent/HUE042391T2/hu unknown
- 2011-06-30 US US13/805,488 patent/US8999920B2/en active Active
- 2011-06-30 MX MX2012014928A patent/MX2012014928A/es active IP Right Grant
- 2011-06-30 EP EP18215066.4A patent/EP3492085A1/en active Pending
- 2011-06-30 EP EP11799979.7A patent/EP2588113B1/en active Active
- 2011-06-30 TW TW100123185A patent/TWI531388B/zh active
- 2011-06-30 JP JP2013516907A patent/JP5989641B2/ja active Active
- 2011-06-30 DK DK11799979.7T patent/DK2588113T3/en active
-
2012
- 2012-12-23 IL IL223815A patent/IL223815A/en active IP Right Grant
-
2015
- 2015-02-27 US US14/633,880 patent/US9439946B2/en active Active
-
2016
- 2016-06-02 JP JP2016110551A patent/JP2016188226A/ja active Pending
- 2016-08-19 US US15/241,895 patent/US10335457B2/en active Active
-
2019
- 2019-06-19 US US16/445,937 patent/US11058747B2/en active Active
-
2021
- 2021-07-06 US US17/368,464 patent/US11723953B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11723953B2 (en) | Reconstituted high density lipoprotein formulation and production method thereof | |
JP5248113B2 (ja) | ペプチドの安定な処方 | |
US11957731B2 (en) | Reconstituted HDL formulation | |
CN107753953B (zh) | 聚乙二醇化激肽原酶的制剂及其应用 | |
DK2916857T3 (en) | RECONSTITUTED HDL FORMULATION |